1
|
Mehlhorn I, Heichel J, Wohlgemuth W, Skalej M, Izaguirre V, Dießel L, Kisser U, Viestenz A, Wienrich R. [Interdisciplinary management of a combined vascular malformation of the orbit]. Ophthalmologie 2024; 121:68-71. [PMID: 37624390 DOI: 10.1007/s00347-023-01900-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/18/2023] [Revised: 07/02/2023] [Accepted: 07/03/2023] [Indexed: 08/26/2023]
Affiliation(s)
- Ivana Mehlhorn
- Klinik und Poliklinik für Augenheilkunde, Martin-Luther-Universität Halle-Wittenberg, Halle, Deutschland.
| | - Jens Heichel
- Klinik und Poliklinik für Augenheilkunde, Martin-Luther-Universität Halle-Wittenberg, Halle, Deutschland
| | - Walter Wohlgemuth
- Klinik und Poliklinik für Radiologie, Martin-Luther-Universität Halle-Wittenberg, Halle, Deutschland
| | - Martin Skalej
- Klinik und Poliklinik für Radiologie, Martin-Luther-Universität Halle-Wittenberg, Halle, Deutschland
| | - Victor Izaguirre
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Martin-Luther-Universität Halle-Wittenberg, Halle, Deutschland
| | - Linda Dießel
- Institut für Pathologie, Martin-Luther-Universität Halle-Wittenberg, Halle, Deutschland
| | - Ulrich Kisser
- Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Kopf- und Halschirurgie, Martin-Luther-Universität Halle-Wittenberg, Halle, Deutschland
| | - Arne Viestenz
- Klinik und Poliklinik für Augenheilkunde, Martin-Luther-Universität Halle-Wittenberg, Halle, Deutschland
| | - Ricarda Wienrich
- Klinik und Poliklinik für Augenheilkunde, Martin-Luther-Universität Halle-Wittenberg, Halle, Deutschland
| |
Collapse
|
2
|
Gkika E, Kostyszyn D, Fechter T, Moustakis C, Ernst F, Boda-Heggemann J, Sarria G, Dieckmann K, Dobiasch S, Duma MN, Eberle F, Kroeger K, Häussler B, Izaguirre V, Jazmati D, Lautenschläger S, Lohaus F, Mantel F, Menzel J, Pachmann S, Pavic M, Radlanski K, Riesterer O, Gerum S, Röder F, Willner J, Barczyk S, Imhoff D, Blanck O, Wittig A, Guckenberger M, Grosu AL, Brunner TB. Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma using different imaging modalities. Strahlenther Onkol 2023; 199:973-981. [PMID: 37268767 PMCID: PMC10598103 DOI: 10.1007/s00066-023-02085-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Accepted: 04/11/2023] [Indexed: 06/04/2023]
Abstract
PURPOSE The aim of this study was to evaluate interobserver agreement (IOA) on target volume definition for pancreatic cancer (PACA) within the Radiosurgery and Stereotactic Radiotherapy Working Group of the German Society of Radiation Oncology (DEGRO) and to identify the influence of imaging modalities on the definition of the target volumes. METHODS Two cases of locally advanced PACA and one local recurrence were selected from a large SBRT database. Delineation was based on either a planning 4D CT with or without (w/wo) IV contrast, w/wo PET/CT, and w/wo diagnostic MRI. Novel compared to other studies, a combination of four metrics was used to integrate several aspects of target volume segmentation: the Dice coefficient (DSC), the Hausdorff distance (HD), the probabilistic distance (PBD), and the volumetric similarity (VS). RESULTS For all three GTVs, the median DSC was 0.75 (range 0.17-0.95), the median HD 15 (range 3.22-67.11) mm, the median PBD 0.33 (range 0.06-4.86), and the median VS was 0.88 (range 0.31-1). For ITVs and PTVs the results were similar. When comparing the imaging modalities for delineation, the best agreement for the GTV was achieved using PET/CT, and for the ITV and PTV using 4D PET/CT, in treatment position with abdominal compression. CONCLUSION Overall, there was good GTV agreement (DSC). Combined metrics appeared to allow a more valid detection of interobserver variation. For SBRT, either 4D PET/CT or 3D PET/CT in treatment position with abdominal compression leads to better agreement and should be considered as a very useful imaging modality for the definition of treatment volumes in pancreatic SBRT. Contouring does not appear to be the weakest link in the treatment planning chain of SBRT for PACA.
Collapse
Affiliation(s)
- E Gkika
- Department of Radiation Oncology, University Medical Center Freiburg, Robert Koch Str 3, Freiburg, Germany.
| | - D Kostyszyn
- Department of Radiation Oncology, University Medical Center Freiburg, Robert Koch Str 3, Freiburg, Germany
| | - T Fechter
- Department of Radiation Oncology, University Medical Center Freiburg, Robert Koch Str 3, Freiburg, Germany
| | - C Moustakis
- Department of Radiation Oncology, University Medical Center Muenster, Muenster, Germany
| | - F Ernst
- Institute for Robotics and Cognitive Systems, University of Luebeck, Luebeck, Germany
| | - J Boda-Heggemann
- Department of Radiation Oncology, Faculty of Medicine Mannheim, Department of Radiation Oncology, University of Heidelberg, Mannheim, Germany
| | - G Sarria
- Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany
| | - K Dieckmann
- Department of Radiation Oncology, University Departments of the MedUni Vienna, Vienna General Hospital, Vienna, Austria
| | - S Dobiasch
- Department of Radiation Oncology, Klinikum Rechts der Isar, TU Munich, Munich, Germany
| | - M N Duma
- Department of Radiotherapy and Radiation Oncology, University Hospital Jena, Friedrich-Schiller University, Jena, Germany
| | - F Eberle
- Department of Radiation Oncology, University Hospital Marburg, Marburg, Germany
| | - K Kroeger
- Department of Radiation Oncology, University Medical Center Muenster, Muenster, Germany
| | - B Häussler
- Radiation Oncology Dr. Häussler/Dr. Schorer, Munich, Germany
| | - V Izaguirre
- Department of Radiation Oncology, University Hospital Halle, Halle, Germany
| | - D Jazmati
- Proton Therapy Centre, University Hospital Essen, Essen, Germany
| | - S Lautenschläger
- Department of Radiation Oncology, University Hospital, Marburg, Germany
| | - F Lohaus
- Department of Radiation Oncology, University Hospital Dresden, Dresden, Germany
| | - F Mantel
- Department of Radiation Oncology, University Hospital Würzburg, Würzburg, Germany
| | - J Menzel
- Department of Radiation Oncology, University Hospital Hannover, Hannover, Germany
| | - S Pachmann
- Department of Radiation Oncology, Weilheim Clinic, Weilheim, Germany
| | - M Pavic
- Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - K Radlanski
- Department of Radiation Oncology, Charite, University Hospital Berlin, Berlin, Germany
| | - O Riesterer
- Centre for Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland
| | - S Gerum
- Department of Radiation Oncology, University Clinic, Paracelsus Medical University (PMU), Salzburg, Austria
| | - F Röder
- Department of Radiation Oncology, University Clinic, Paracelsus Medical University (PMU), Salzburg, Austria
| | - J Willner
- Department of Radiation Oncology, University Hospital Bayreuth, Bayreuth, Germany
| | - S Barczyk
- Center for Radiation Oncology, Belegklinik am St. Agnes-Hospital, Bocholt, Germany
| | - D Imhoff
- Department of Radiation Oncology, Saphir Radiosurgery, University Hospital Frankfurt, Frankfurt, Germany
| | - O Blanck
- Saphir Radiosurgery, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - A Wittig
- Department of Radiotherapy and Radiation Oncology, University Hospital Jena, Friedrich-Schiller University, Jena, Germany
| | - M Guckenberger
- Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Anca-L Grosu
- Department of Radiation Oncology, University Medical Center Freiburg, Robert Koch Str 3, Freiburg, Germany
| | - T B Brunner
- Department of Therapeutic Radiology and Oncology, Comprehensive Cancer Center, Medical University of Graz, Graz, Austria
| |
Collapse
|
3
|
Buergy D, Würschmidt F, Gkika E, Hörner-Rieber J, Knippen S, Gerum S, Balermpas P, Henkenberens C, Voglhuber T, Kornhuber C, Barczyk S, Röper B, Rashid A, Blanck O, Wittig A, Herold HU, Brunner TB, Sweeney RA, Kahl KH, Ciernik FI, Ottinger A, Izaguirre V, Putz F, König L, Hoffmann M, Combs SE, Guckenberger M, Boda-Heggemann J. Stereotactic Body Radiotherapy of adrenal metastases - A dose-finding study. Int J Cancer 2022; 151:412-421. [PMID: 35383919 DOI: 10.1002/ijc.34017] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2022] [Revised: 02/22/2022] [Accepted: 03/08/2022] [Indexed: 11/12/2022]
Abstract
Optimal doses for the treatment of adrenal metastases with stereotactic radiotherapy (SBRT) are unknown. We aimed to identify dose-volume cut-points associated with decreased local recurrence rates (LRR). A multicenter database of patients with adrenal metastases of any histology treated with SBRT (biologically effective dose, BED10 ≥ 50Gy, ≤ 12 fractions) was analyzed. Details on dose-volume parameters were required (planning target volume: PTV-D98%, PTV-D50%, PTV-D2%; gross tumor volume: GTV-D50%, GTV-mean). Cut-points for LRR were optimized using the R maxstat package. 196 patients with 218 lesions were included, the largest histopathological subgroup was adenocarcinoma (n = 101). Cut-point optimization resulted in significant cut-points for PTV-D50% (BED10: 73.2Gy; p = 0.003), GTV-D50% (BED10: 74.2Gy; p = 0.006), GTV-mean (BED10: 73.0Gy; p = 0.007), and PTV-D2% (BED10: 78.0Gy; p = 0.02) but not for the PTV-D98% (p = 0.06). Differences in LRR were clinically relevant (LRR ≥ doubled for cut-points that were not achieved). Further dose-escalation was not associated with further improved LRR. PTV-D50%, GTV-D50%, and GTV-mean cut-points were also associated with significantly improved LRR in the adenocarcinoma subgroup. Separate dose optimizations indicated a lower cut-point for the PTV-D50% (BED10: 69.1Gy) in adenocarcinoma lesions, other values were similar (< 2% difference). Associations of cut-points with overall survival (OS) and progression-free survival were not significant but durable freedom from local recurrence was associated with OS in a landmark model (p < 0.001). To achieve a significant improvement of LRR for adrenal SBRT, a moderate escalation of PTV-D50% BED10 > 73.2Gy (adenocarcinoma: 69.1Gy) should be considered. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Daniel Buergy
- Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Klinik für Strahlentherapie und Radioonkologie, Mannheim, Deutschland
| | | | - Eleni Gkika
- Universitätsklinikum Freiburg, Strahlenheilkunde, Freiburg, Deutschland
| | - Juliane Hörner-Rieber
- Universitätsklinikum Heidelberg, Klinik für Radioonkologie und Strahlentherapie, Heidelberg, Deutschland
| | - Stefan Knippen
- Universitätsklinikum Jena, Klinik für Strahlentherapie und Radioonkologie, Jena, Deutschland.,Universitätsklinikum Erlangen, Strahlenklinik, Erlangen, Deutschland
| | - Sabine Gerum
- Radioonkologie LMU München, Strahlentherapie und Radioonkologie, München, Deutschland.,Klinik für Radiotherapie und Radioonkologie, Paracelsus Universität Salzburg, Landeskrankenhaus, Salzburg, Österreich
| | - Panagiotis Balermpas
- Universitätsspital Zürich, Universität Zürich, Klinik für Radio-Onkologie, Zürich, Schweiz
| | - Christoph Henkenberens
- Medizinische Hochschule Hannover, Klinik für Strahlentherapie und Spezielle Onkologie, Hannover, Deutschland
| | - Theresa Voglhuber
- Technische Universität München (TUM), Department of Radiation Oncology, Ismaninger Straße 22, Munich
| | - Christine Kornhuber
- Universitätsklinikum Halle (Saale), Klinik für Strahlentherapie, Halle (Saale), Deutschland
| | - Steffen Barczyk
- Zentrum für Strahlentherapie und Radioonkologie, Belegklinik am St. Agnes-Hospital, Bocholt, Deutschland
| | - Barbara Röper
- DIE RADIOLOGIE, MVZ Strahlentherapie Bogenhausen - Harlaching - Neuperlach, München, Deutschland
| | - Ali Rashid
- MediClin Robert Janker Klinik, Klinik für Strahlentherapie und Radioonkologie, Bonn, Deutschland
| | - Oliver Blanck
- Universitätsklinikum Schleswig-Holstein, Klinik für Strahlentherapie, Kiel, Deutschland
| | - Andrea Wittig
- Universitätsklinikum Jena, Klinik für Strahlentherapie und Radioonkologie, Jena, Deutschland
| | - Hans-Ulrich Herold
- Cyberknife Centrum Mitteldeutschland GmbH, Institut für Radiochirurgie und Präzisionsbestrahlung, Erfurt, Deutschland
| | - Thomas B Brunner
- Universitätsklinikum Magdeburg, Klinik für Strahlentherapie, Magdeburg, Deutschland
| | - Reinhart A Sweeney
- Leopoldina Krankenhaus Schweinfurt, Klinik für Strahlentherapie, Schweinfurt, Deutschland
| | - Klaus Henning Kahl
- Universitätsklinikum Augsburg, Klinik für Strahlentherapie und Radioonkologie, Augsburg, Deutschland
| | - F Ilja Ciernik
- Städtisches Klinikum Dessau, Klinik für Strahlentherapie und Radioonkologie, Dessau, Deutschland
| | - Annette Ottinger
- Klinikum Darmstadt GmbH, Institut für Radioonkologie und Strahlentherapie, Darmstadt, Deutschland
| | - Victor Izaguirre
- Universitätsklinikum Halle (Saale), Klinik für Strahlentherapie, Halle (Saale), Deutschland
| | - Florian Putz
- Universitätsklinikum Erlangen, Strahlenklinik, Erlangen, Deutschland
| | - Laila König
- Universitätsklinikum Heidelberg, Klinik für Radioonkologie und Strahlentherapie, Heidelberg, Deutschland
| | - Michael Hoffmann
- Radioonkologie LMU München, Strahlentherapie und Radioonkologie, München, Deutschland
| | - Stephanie E Combs
- Technische Universität München (TUM), Department of Radiation Oncology, Ismaninger Straße 22, Munich.,Helmholtz Zentrum München (HMGU), Ingolstädter Landstraße 1, Neuherberg, Deutschland.,Deutsches Zentrum für Translationale Krebsforschung (DKTK) Partner Site Munich
| | - Matthias Guckenberger
- Universitätsspital Zürich, Universität Zürich, Klinik für Radio-Onkologie, Zürich, Schweiz
| | - Judit Boda-Heggemann
- Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Klinik für Strahlentherapie und Radioonkologie, Mannheim, Deutschland
| |
Collapse
|
4
|
Buergy D, Würschmidt F, Gkika E, Hörner-Rieber J, Knippen S, Gerum S, Balermpas P, Henkenberens C, Voglhuber T, Kornhuber C, Barczyk S, Röper B, Rashid A, Blanck O, Wittig A, Herold HU, Brunner TB, Klement RJ, Kahl KH, Ciernik IF, Ottinger A, Izaguirre V, Putz F, König L, Hoffmann M, Combs SE, Guckenberger M, Boda-Heggemann J. Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis. Int J Cancer 2021; 149:358-370. [PMID: 33682927 DOI: 10.1002/ijc.33546] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2020] [Revised: 02/01/2021] [Accepted: 02/11/2021] [Indexed: 01/17/2023]
Abstract
To report outcome (freedom from local progression [FFLP], overall survival [OS] and toxicity) after stereotactic, palliative or highly conformal fractionated (>12) radiotherapy (SBRT, Pall-RT, 3DCRT/IMRT) for adrenal metastases in a retrospective multicenter cohort within the framework of the German Society for Radiation Oncology (DEGRO). Adrenal metastases treated with SBRT (≤12 fractions, biologically effective dose [BED10] ≥ 50 Gy), 3DCRT/IMRT (>12 fractions, BED10 ≥ 50 Gy) or Pall-RT (BED10 < 50 Gy) were eligible for this analysis. In addition to unadjusted FFLP (Kaplan-Meier/log-rank), we calculated the competing-risk-adjusted local recurrence rate (CRA-LRR). Three hundred twenty-six patients with 366 metastases were included by 21 centers (median follow-up: 11.7 months). Treatment was SBRT, 3DCRT/IMRT and Pall-RT in 260, 27 and 79 cases, respectively. Most frequent primary tumors were non-small-cell lung cancer (NSCLC; 52.5%), SCLC (16.3%) and melanoma (6.7%). Unadjusted FFLP was higher after SBRT vs Pall-RT (P = .026) while numerical differences in CRA-LRR between groups did not reach statistical significance (1-year CRA-LRR: 13.8%, 17.4% and 27.7%). OS was longer after SBRT vs other groups (P < .05) and increased in patients with locally controlled metastases in a landmark analysis (P < .0001). Toxicity was mostly mild; notably, four cases of adrenal insufficiency occurred, two of which were likely caused by immunotherapy or tumor progression. Radiotherapy for adrenal metastases was associated with a mild toxicity profile in all groups and a favorable 1-year CRA-LRR after SBRT or 3DCRT/IMRT. One-year FFLP was associated with longer OS. Dose-response analyses for the dataset are underway.
Collapse
Affiliation(s)
- Daniel Buergy
- Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Klinik für Strahlentherapie und Radioonkologie, Mannheim, Germany
| | | | - Eleni Gkika
- Universitätsklinikum Freiburg, Strahlenheilkunde, Freiburg, Germany
| | - Juliane Hörner-Rieber
- Universitätsklinikum Heidelberg, Klinik für Radioonkologie und Strahlentherapie, Heidelberg, Germany
| | - Stefan Knippen
- Universitätsklinikum Jena, Klinik für Strahlentherapie und Radioonkologie, Jena, Germany.,Universitätsklinikum Erlangen, Strahlenklinik, Erlangen, Germany
| | - Sabine Gerum
- Radioonkologie LMU München, Strahlentherapie und Radioonkologie, Munich, Germany.,Klinik für Radiotherapie und Radioonkologie, Paracelsus Universität Salzburg, Landeskrankenhaus, Salzburg, Austria
| | - Panagiotis Balermpas
- Universitätsspital Zürich, Universität Zürich, Klinik für Radio-Onkologie, Zürich, Switzerland
| | - Christoph Henkenberens
- Medizinische Hochschule Hannover, Klinik für Strahlentherapie und Spezielle Onkologie, Hannover, Germany
| | - Theresa Voglhuber
- Technische Universität München (TUM), Department of Radiation Oncology, Munich, Germany
| | - Christine Kornhuber
- Universitätsklinikum Halle (Saale), Klinik für Strahlentherapie, Halle (Saale), Germany
| | - Steffen Barczyk
- Zentrum für Strahlentherapie und Radioonkologie, Belegklinik am St. Agnes-Hospital, Bocholt, Germany
| | - Barbara Röper
- Gemeinschaftspraxis für Strahlentherapie, Bogenhausen - Harlaching - Neuperlach, Munich, Germany
| | - Ali Rashid
- MediClin Robert Janker Klinik, Klinik für Strahlentherapie und Radioonkologie, Bonn, Germany
| | - Oliver Blanck
- Universitätsklinikum Schleswig-Holstein, Klinik für Strahlentherapie, Kiel, Germany
| | - Andrea Wittig
- Universitätsklinikum Jena, Klinik für Strahlentherapie und Radioonkologie, Jena, Germany
| | - Hans-Ulrich Herold
- Cyberknife Centrum Mitteldeutschland GmbH, Institut für Radiochirurgie und Präzisionsbestrahlung, Erfurt, Germany
| | - Thomas B Brunner
- Universitätsklinikum Magdeburg, Klinik für Strahlentherapie, Magdeburg, Germany
| | - Rainer J Klement
- Universitätsspital Zürich, Universität Zürich, Klinik für Radio-Onkologie, Zürich, Switzerland.,Leopoldina Krankenhaus Schweinfurt, Klinik für Strahlentherapie, Schweinfurt, Germany
| | - Klaus Henning Kahl
- Universitätsklinikum Augsburg, Klinik für Strahlentherapie und Radioonkologie, Augsburg, Germany
| | - Ilja F Ciernik
- Städtisches Klinikum Dessau, Klinik für Strahlentherapie und Radioonkologie, Dessau, Germany
| | - Annette Ottinger
- Klinikum Darmstadt GmbH, Institut für Radioonkologie und Strahlentherapie, Darmstadt, Germany
| | - Victor Izaguirre
- Universitätsklinikum Halle (Saale), Klinik für Strahlentherapie, Halle (Saale), Germany
| | - Florian Putz
- Universitätsklinikum Erlangen, Strahlenklinik, Erlangen, Germany
| | - Laila König
- Universitätsklinikum Heidelberg, Klinik für Radioonkologie und Strahlentherapie, Heidelberg, Germany
| | - Michael Hoffmann
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum der Universität München, LMU, Munich, Germany
| | - Stephanie E Combs
- Technische Universität München (TUM), Department of Radiation Oncology, Munich, Germany.,Helmholtz Zentrum München (HMGU), Neuherberg, Germany.,Deutsches Zentrum für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany
| | - Matthias Guckenberger
- Universitätsspital Zürich, Universität Zürich, Klinik für Radio-Onkologie, Zürich, Switzerland
| | - Judit Boda-Heggemann
- Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Klinik für Strahlentherapie und Radioonkologie, Mannheim, Germany
| |
Collapse
|
5
|
Ostheimer C, Ensminger S, Janich M, Sieker F, Izaguirre V, Gerlach R, Vordermark D. EP-1869: Dosimetric plan comparison of VMAT vs. IMRT in 257 patients with head-and-neck and prostate cancer. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32178-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Jimenez KL, Zavaleta AI, Izaguirre V, Yarleque A, Inga RR. [Molecular cloning and characterization in silico of phospholipase A(2) transcript isolated from Lachesis muta peruvian snake venom]. Rev Peru Med Exp Salud Publica 2011; 27:532-9. [PMID: 21308192 DOI: 10.1590/s1726-46342010000400007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
OBJECTIVE Isolate and characterize in silico gene phospholipase A(2) (PLA(2)) isolated from Lachesis muta venom of the Peruvian Amazon. MATERIAL AND METHODS Technique RT-PCR from total RNA was using specific primers, the amplified DNA product was inserted into the pGEM vector for subsequent sequencing. By bioinformatic analysis identified an open reading frame of 414 nucleotides that encoded 138 amino acids including a signal peptide of 16 aminoacids, molecular weight and pI were 13,976 kDa and 5.66 respectively. RESULTS The aminoacid sequence was called Lm-PLA(2)-Peru, contains an aspartate at position 49, this aminoacid in conjunction with other conserved residues such as Tyr-28, Gly-30, Gly-32, His-48, Tyr52, Asp99 are important for enzymatic activity. The comparison with the amino acid sequence data banks showed of similarity between PLA(2) from Lachesis stenophrys (93%) and other PLA(2) snake venoms and over 80% of other sPLA(2) family Viperidae venoms. A phylogenetic analysis showed that Lm-PLA(2)-Peru grouped with other acidic [Asp(49)] sPLA(2) previously isolated from Bothriechis schlegelii venom showing 89 % nucleotide sequence identity. Finally, the computer modeling indicated that enzyme had the characteristic structure of sPLA(2) group II that consisted of three α-helices, a β-wing, a short helix and a calcium-binding loop. CONCLUSION The nucleotide sequence corresponding to the first transcript of gene from PLA(2) cloned of Lachesis muta venom, snake from the Peruvian rainforest.
Collapse
Affiliation(s)
- Karim L Jimenez
- Laboratorio de Biología Molecular, Facultad de Farmacia y Bioquímica, Universidad Nacional Mayor de San Marcos, Lima, Perú.
| | | | | | | | | |
Collapse
|
7
|
Jimenez KL, Zavaleta AI, Izaguirre V, Yarleque A, Inga RR. Clonaje caracterización molecular in silico de un transcrito de fosfolipasa A, aislado del veneno de la serpiente peruana Lachesis muta. Rev Peru Med Exp Salud Publica 2010. [DOI: 10.17843/rpmesp.2010.274.1524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
8
|
Tomé AR, Izaguirre V, Rosário LM, Ceña V, González-García C. Naloxone inhibits nicotine-induced receptor current and catecholamine secretion in bovine chromaffin cells. Brain Res 2001; 903:62-5. [PMID: 11382388 DOI: 10.1016/s0006-8993(01)02388-5] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Nicotine-induced catecholamine (CA) secretion and inward ionic currents were inhibited by the opioid antagonist naloxone in cultured bovine chromaffin cells. Naloxone inhibited nicotine-induced CA secretion, as detected by an on-line real-time electrochemical technique, in a dose-dependent manner (IC(50)=29 microM). In voltage-clamped chromaffin cells, nicotine (10 microM) evoked an average peak inward current of -146 pA that was inhibited by low concentrations of naloxone (42% at 0.1 microM). The antagonist also inhibited total charge influx associated with nicotinic receptor activation (53% at 0.1 microM). This provides strong evidence that naloxone modulation of nicotine-induced CA secretion does not involve opioid receptors but results from the direct interaction with the nicotinic receptor itself, which might also be the case for other related opioid compounds.
Collapse
Affiliation(s)
- A R Tomé
- Department of Biochemistry, Faculty of Sciences and Technology, University of Coimbra, Coimbra, Portugal
| | | | | | | | | |
Collapse
|
9
|
Izaguirre V, Fernández-Fernández JM, Ceña V, González-García C. Tricyclic antidepressants block cholinergic nicotinic receptors and ATP secretion in bovine chromaffin cells. FEBS Lett 1997; 418:39-42. [PMID: 9414091 DOI: 10.1016/s0014-5793(97)01343-4] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Nicotine-induced ATP secretion from chromaffin cells was blocked by imipramine and desipramine. This blocking action took place on both, fast and slow, components of ATP secretion. Exposure of chromaffin cells to nicotine (10 microM) for 4 s induced an inward current of about -155 pA. Imipramine and desipramine blocked, in a concentration-dependent manner, both peak inward current and total charge influx in response to nicotine. In addition, imipramine and desipramine partially (40%) blocked depolarization-induced ATP secretion and Ca2+ currents evoked by high K+. This suggests that tricyclic antidepressants block nicotine-induced ATP secretion by acting on two targets: one is the nicotinic receptor itself and the second one are voltage-dependent Ca2+ channels.
Collapse
Affiliation(s)
- V Izaguirre
- Departamento de Farmacología and Instituto de Neurociencias, Universidad Miguel Hernández, Campus de San Juan, Alicante, Spain
| | | | | | | |
Collapse
|
10
|
Granja R, Izaguirre V, Calvo S, González-García C, Ceña V. Extracellular calcium has distinct effects on fast and slow components of the depolarization-induced secretory response from chromaffin cells. J Neurochem 1996; 67:1056-62. [PMID: 8752112 DOI: 10.1046/j.1471-4159.1996.67031056.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
An increase in extracellular Ca2+ concentration from 0.25 to 10 mM enhanced secretion of norepinephrine and epinephrine induced by a high extracellular K+ concentration (75 mM). The increment in extracellular Ca2+ concentration also increased the observed peak inward Ca2+ current in response to long (10-s) depolarizing pulses from a holding potential of -55 mV to +5 mV, from about -26 to -400 pA. However, the total amount of Ca2+ influx into the cell only increased when the extracellular Ca2+ concentration was raised from 0.25 to 1 mM and then remained constant up to 10 mM extracellular Ca2+. ATP is cosecreted with catecholamines following a depolarizing stimulus. Kinetic studies indicated that ATP secretion had two components with time constants, in the presence of 2.5 mM extracellular Ca2+, of approximately 4 and 41 s, being the fast component of secretion produced by the exocytosis of approximately 220 chromaffin granules. The results suggest that, for a given depolarizing stimulus, the size and rate of release for the fast and slow components of secretion are dependent on extracellular Ca2+ concentration.
Collapse
Affiliation(s)
- R Granja
- Departamento de Farmacología, Universidad de Alicante, Spain
| | | | | | | | | |
Collapse
|
11
|
Fernández JM, Granja R, Izaguirre V, González-García C, Ceña V. omega-Conotoxin GVIA blocks nicotine-induced catecholamine secretion by blocking the nicotinic receptor-activated inward currents in bovine chromaffin cells. Neurosci Lett 1995; 191:59-62. [PMID: 7659292 DOI: 10.1016/0304-3940(95)11558-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We have studied the contribution of N-type voltage-dependent Ca2+ channels to both norepinephrine and epinephrine secretion from bovine chromaffin cells induced by high K+ or nicotine using omega-conotoxin GVIA, a selective blocker of N-type voltage-dependent Ca2+ channels. We found that high K+ (75 mM) induced catecholamine secretion was not affected by exposure of bovine chromaffin cells to omega-conotoxin GVIA (1 microM). However, nicotine-induced both norepinephrine and epinephrine secretion were similarly blocked (about 25%) by omega-conotoxin GVIA (1 microM). This effect could be explained by a potent (about 80%) and reversible blockade of the inward current induced by nicotine receptor activation in bovine chromaffin cells. The results indicate that besides the blockade of N-type voltage-dependent channels, omega-conotoxin GVIA is a potent and reversible blocker of the nicotinic receptor-induced currents in chromaffin cells.
Collapse
Affiliation(s)
- J M Fernández
- Departamento de Farmacología, Universidad de Alicante, Spain
| | | | | | | | | |
Collapse
|
12
|
Granja R, Fernández-Fernández JM, Izaguirre V, González-García C, Ceña V. omega-Agatoxin IVA blocks nicotinic receptor channels in bovine chromaffin cells. FEBS Lett 1995; 362:15-8. [PMID: 7698345 DOI: 10.1016/0014-5793(95)00149-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We have studied the contribution of P-type voltage-dependent Ca2+ channels to both catacholamine (CA) and ATP secretion from bovine chromaffin cells induced by high K+ or nicotine using omega-agatoxin IVA, a selective blocker of P-type voltage-dependent Ca2+ channels. We found that high K+ (75 mM) induced the release of about 13% of norepinephrine, 5% epinephrine and 11% ATP, and that omega-agatoxin (100 nM) did not affect this secretion. However, both nicotine-induced CA and ATP secretion were significantly blocked (about 50%) by omega-agatoxin IVA (100 nM). In addition, this toxin also reversibly blocked (about 70%) the inward current induced by nicotine in bovine chromaffin cells. The results suggest that, besides its known action of blocking P-type voltage-dependent channels, omega-agatoxin is a potent and reversible blocker of the nicotinic receptor channel in chromaffin cells, and that this action would explain the blockade of nicotine-induced secretion.
Collapse
Affiliation(s)
- R Granja
- Departamento de Farmacología, Universidad de Alicante, Spain
| | | | | | | | | |
Collapse
|
13
|
Izaguirre V, Vargas M, León-Velarde F, Huicho L, Monge C, Barcelò AC, Alippi RM, Bozzini CE. Inhibitory effect of an alpha 1-adrenergic antagonist on erythropoiesis in normoxic or hypoxic mice. Int J Clin Lab Res 1994; 24:213-6. [PMID: 7894046 DOI: 10.1007/bf02592465] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The present study was undertaken to assess the effect of prazosin, a selective postsynaptic alpha 1-adrenergic receptor blocking agent, on normoxic and hypoxic mice, in order to evaluate experimentally its use in the treatment of the excessive erythrocytosis that characterizes chronic mountain sickness. The drug, injected intraperitoneally to adult mice at a dose of 400 micrograms/kg per day, induced a significant depression of the rate or erythropoiesis, as measured by red blood cell 59iron uptake, with a decrease in the hematocrit from the 3rd day. The drug also inhibited the oxygen-dependent secretion of erythropoietin (estimated by the plasma immunoreactive hormone concentration) in hypoxemic mice when injected between 0 and 2 h after initiation of the hypoxic stimulation. When injected daily into mice exposed to intermittent hypobaric hypoxia, prazosin limited the degree of polycythemia or induced a sustained decrease in the hematocrit when polycythemia was already present due to previous exposure. It is postulated that the drug, by reducing the peripheral vascular resistance seen during hypoxia, could increase renal blood flow, thus improving the renal oxygen supply and partially restoring the imbalance between gas supply and demand, which drives erythropoietin formation.
Collapse
Affiliation(s)
- V Izaguirre
- Department of Physiological Sciences, C Heredia University, Lima, Perù
| | | | | | | | | | | | | | | |
Collapse
|